FIELD: pharmacy.
SUBSTANCE: combination of antibiotics containing rifabutin, clarithromycin and clofazimine for treatment of autoimmune diseases such as multiple sclerosis.
EFFECT: increased efficiency of treatment.
16 cl, 5 tbl, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TYPES OF COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2727474C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS USING LSD1 INHIBITOR | 2017 |
|
RU2768120C2 |
| LACTOBACILLUS APPLICATION FOR TREATING AUTOIMMUNE DISEASES | 2006 |
|
RU2417092C2 |
| NEW METHODS FOR TREATING MULTIPLE SCLEROSIS | 2018 |
|
RU2765820C2 |
| GENE-CELL VESICULAR THERAPEUTIC DRUG AND METHOD FOR MULTIPLE SCLEROSIS THERAPY BY TRANSPLANTATION OF A GENE-CELL VESICULAR THERAPEUTIC DRUG | 2021 |
|
RU2762855C1 |
| METHOD FOR TREATING AUTOIMMUNE DISEASES USING TYPE 1 INTERFERONS | 1995 |
|
RU2166959C2 |
| TREATMENT OF DEMYELINATING DISEASES | 2019 |
|
RU2805061C2 |
| APPLICATION OF 5'-METHYLTHIOADENOSINE (MTA) FOR PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR GRAFT REJECTION | 2005 |
|
RU2393866C2 |
| RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
| TREATMENT OF AUTOIMMUNE REACTION AND MULTIPLE SCLEROSIS | 2015 |
|
RU2687750C2 |
